-
Mashup Score: 1
Among patients with newly diagnosed myeloma, survival in recipients of a hematopoietic stem-cell autograft followed by a stem-cell allograft from an HLA-identical sibling is superior to that in recipients of tandem stem-cell autografts. (ClinicalTrials.gov number, NCT00415987 [ClinicalTrials.gov].).
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
In patients with previously untreated multiple myeloma, long-term outcome with respect to progression-free survival, overall survival, and relapse rate is superior after auto-allo compared with auto only. Nonrelapse mortality is at a reasonable level in both groups.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
@barttels2 @rajshekharucms @RahulBanerjeeMD @Drjhoffmanmiami @GKaurMD @AaronGoodman33 @ManniMD1 @EagleMyeloma @BijoyTelivala @VincentRK @Abdallah81MD @OncBrothers @Rfonsi1 Originally it was a partly facetious comment but there are better data for this than quad maintenance etc that’s being proposed https://t.co/DQh9AOvcvj
-
-
Mashup Score: 4
8506 Background: STaMINA was a phase III trial comparing progression-free survival (PFS) among 758 pts randomized to: 1. second autoHCT then lenalidomide (Len) maintenance (Auto/Auto, n = 247); 2. consolidation with Len/bortezomib/ dexamethasone (RVD) followed by Len maintenance (Auto/RVD, 254); 3. Len maintenance (Auto/Len, 257). All three arms were similar (Stadtmauer JCO 2018). Len maintenance was designed to continue for 3 years and amended to allow continuation until disease progression through a follow up protocol (07LT, NCT#02322320). We report 6 yr follow up for STaMINA and the results of Len discontinuation beyond 3 years. Methods: 07LT was offered to pts who were progression-free at 38 mo; completed planned Len maintenance and were within 4 years of BMT CTN 0702 follow up. Among 431 07LT eligible patients, 273 enrolled and 179 opted to continue maintenance until disease progression. All patients enrolled in STaMINA were reported to the Center for International Blood and Marro
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
@ManniMD1 @nihardesai7 Available evidence : even if progression is sooner after Len stops ; no OS difference.. landmark analysis of STaMiNa trial of stopping at 3 yrs vs. continuing https://t.co/qALFyK8VnH
-
-
Mashup Score: 2
Allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment modality for primary myelofibrosis (MF) and related myeloproliferative neoplasms. Older age at diagnosis and age-related comorbidities make most patients ineligible for allo-HCT, given concerns for nonrelapse mor …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
@BijoyTelivala @AaronGoodman33 Nothing wrong with selecting patients, timing and center for a high risk high reward intervention… We saw about 200 referrals in 10 years to do 37 transplants - ~80% RFS at 3 yrs. https://t.co/6UskfIbXxp
-
-
Mashup Score: 0Learning to mellow out GVHD - 8 month(s) ago
In this issue of Blood, Yuan et al demonstrated that cannabinoids modulate the adoptive and innate immune responses involved in the regulation of acute and chro
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
@AaronGoodman33 Do not wish to debate decision making in the absence of nature data- merely pointing out that cannabinoids have a lot of fairly strong data (IMHO) suggesting they are immune suppressive. E.g - in GVHD and without the need to cherry pick papers https://t.co/xFsyPF4UXA
-
-
Mashup Score: 0
Cyclophosphamide (CY) is a cytotoxic and immunomodulating agent that is commonly used in hematopoietic cell transplantation (HCT). Because of its critical role in HCT, either under- or overexposure to high-dose CY (e.g., 50-60 mg/kg/dose) can lead to detrimental consequences with relapse or treatment-related mortality in myeloablative or autologous HCT, respectively [1]. We recently reported that…
Categories: Hem/Oncs, Latest HeadlinesTweet-
@MediHumdani @Tim3Stock CY obesity adjustment is tricky .. this study is interesting- https://t.co/UlrEccX5Ko
-
-
Mashup Score: 3A Patient-Centric Platform for Cancer | MyCancerHaven - 1 year(s) ago
MyCancerHaven is a patient-centric platform for cancer. A user-funded non profit organization, online forum for patient community, experts, family and friends
Source: www.mycancerhaven.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @My_Cancer_Haven: MCH: Founded and Designed by An Academic Expert Join us: https://t.co/XIinFH8XB9 Follow @My_Cancer_Haven #mmsm #Can…
-
-
Mashup Score: 0
A relatively high proportion of patients diagnosed with primary CNS lymphoma will experience recurrent disease, yet therapy options are limited in salvage therapy. This is the first study to evaluate a bendamustine-based combination regimen for the treatment …
Source: PubMed Central (PMC)Categories: Hem/Oncs, Latest HeadlinesTweet-
@timfenske @rajshekharucms @Rfonsi1 @bdermanmd @AaronGoodman33 https://t.co/GQPXf9ATfR
-
-
Mashup Score: 0Quordle - 2 year(s) ago
Put your skills to the test and solve four Wordles at once! You have 9 guesses to solve all four words. A new Quordle available each day to solve.
Source: www.quordle.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Daily Quordle #28 7️⃣3️⃣ 5️⃣4️⃣ https://t.co/pbSue4Z5x3
-
-
Mashup Score: 3Sarah Cannon appoints deputy physician-in-chief of blood cancers - 3 year(s) ago
Navneet Majhail, MD, MS, FASTCT, has been appointed deputy physician-in-chief of blood cancers for Sarah Cannon Transplant and Cellular Therapy Network.Majhail also will serve as program medical director for Sarah Cannon transplant and cellular therapy program at Centennial Medical Center in Nashville.
Source: www.healio.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @HemOncToday: Sarah Cannon appoints Navneet Majhail, MD, as deputy physician-in-chief of blood cancers https://t.co/0oNDSdjjjj @SarahCan…
-
@barttels2 @rajshekharucms @RahulBanerjeeMD @Drjhoffmanmiami @GKaurMD @AaronGoodman33 @ManniMD1 @EagleMyeloma @BijoyTelivala @VincentRK @Abdallah81MD @OncBrothers @Rfonsi1 And this too .. not anecdata. But done in an era before the PFS prolonging drugs. https://t.co/9gDUKyx34U